Patents Assigned to Takeda Pharmaceutical Company Limited
  • Publication number: 20210316068
    Abstract: According to various aspects of the present application, embodiments of an infusion pump for administering medication to a patient are provided. According to one embodiment, the infusion pump automatically determines time intervals and associated rates of infusion of the medication, and automatically controls a pump engine to infuse the medication for the determined time intervals at the associated rates of infusion. According to another embodiment, the infusion pump determines whether an infusion set is configured to infuse medication into a patient at one site or at two sites. The infusion pump then controls the pump engine based on the determined configuration of the infusion set. According to another embodiment, the infusion pump automatically primes the infusion set for infusion of medication into a patient. According to another embodiment, the infusion pump automatically determines whether one or more needles have been placed on the patient correctly.
    Type: Application
    Filed: September 24, 2019
    Publication date: October 14, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Angela Teresa Muriset, Thomas Benjamin Roush, Madeleine Clare Gibson, Andrew Scott Argersinger
  • Publication number: 20210309712
    Abstract: The present invention provides immune cells (such as CAR-T cells) having higher antitumor activity than immune cells (such as CAR-T cells) expressing a CAR alone (not expressing cytokines and/or chemokines). A T cell provided in one aspect of the present invention expresses (1) a chimeric antigen receptor (CAR), (2) at least one selected from the group consisting of interleukin-15 (IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), and interleukin-27 (IL-27), and (3) CC chemokine ligand 19 (CCL19).
    Type: Application
    Filed: August 30, 2019
    Publication date: October 7, 2021
    Applicants: NOILE-IMMUNE BIOTECH, INC., Takeda Pharmaceutical Company Limited
    Inventors: Chihiro TAKE, Takayuki TATAMIYA, Akiko YAMAGUCHI
  • Patent number: 11136350
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 5, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nuernberger, Wolfgang Teschner, Harald Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • Patent number: 11130777
    Abstract: The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(?-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: September 28, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Gerard Coquerel, Guillaume Levilain, Marie-Noelle Petit, Servane Coste-Leconte
  • Patent number: 11129828
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 28, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • Publication number: 20210292708
    Abstract: An object of the present invention is to provide a novel approach that enables definitive endoderm cells or insulin-producing cells to be efficiently induced and/or manufactured from pluripotent stem cells. The present invention provides a method for producing definitive endoderm cells from pluripotent stem cells, comprising subjecting pluripotent stem cells to first culture in a differentiation-inducing medium in which insulin acts and subsequently to second culture in a differentiation-inducing medium in which insulin does not act.
    Type: Application
    Filed: August 2, 2019
    Publication date: September 23, 2021
    Applicants: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Noriko YAMAZOE, Hideyuki HIYOSHI, Taro TOYODA
  • Patent number: 11123704
    Abstract: An antibody-resin coupling apparatus quickly and efficiently activates resin beads and couples them to antibodies, while preventing breakdown and crosslinking of the beads, thereby improving downstream column purification processes, extending the usable life of the resin beads, and increasing molecule capture efficiency of the resultant resin-antibody complexes, to allow improved isolation and purification of factor VIII molecules or other drug compounds.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: September 21, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Robert Toso, Richard Spanggord, Mei Tan, Van Tairiol, Yekaterina Lin
  • Patent number: 11124787
    Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: September 21, 2021
    Assignees: Takeda Pharmaceutical Company Limited, Children's Medical Center Corporation
    Inventors: Denisa D. Wagner, Anil Kumar Chauhan, Friedrich Scheiflinger, Barbara Plaimauer
  • Patent number: 11116823
    Abstract: The invention provides methods of treating ?-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human ?-galactosidase A are also included.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: September 14, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Douglas A. Treco, Kenneth Loveday, Marianne Borowski
  • Publication number: 20210275614
    Abstract: A triple-plasmid system for producing recombinant adeno-associated viruses is disclosed.
    Type: Application
    Filed: October 24, 2019
    Publication date: September 9, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Vivian CHOI, Xing LI
  • Publication number: 20210276949
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: April 23, 2021
    Publication date: September 9, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi HATTORI, Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Norihito TOKUNAGA, Alexander Martin PAWLICZEK, Tsuneo ODA, Tohru MIYAZAKI, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO
  • Publication number: 20210269420
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 27, 2019
    Publication date: September 2, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Koichiro FUKUDA, Hiromichi SUGIMOTO, Kentaro RIKIMARU, Yoshihiro BANNO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Yoshihide TOMATA, Yuji ISHICHI, Shogo MARUI, Tsuneo ODA, Tohru MIYAZAKI, Yasutaka HOASHI, Yasushi HATTORI, Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE
  • Publication number: 20210270842
    Abstract: The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.
    Type: Application
    Filed: January 5, 2021
    Publication date: September 2, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Janja Cosic
  • Publication number: 20210262044
    Abstract: To provide a qPCR probe and the like as a novel means for enabling the detection of human cells transplanted or administered to non-human animals. A quantitative PCR probe comprising: a sequence hybridizable with an oligonucleotide consisting of a sequence of 10 to 35 contiguous bases from within a predetermined nucleotide sequence derived from the human LINE-1 gene, and a labeling part. The quantitative PCR probe can be used, for example, in the production of a quantitative PCR kit further comprising a forward primer derived from human LINE-1 and a reverse primer derived from human LINE-1 (the individual sequences are in a predetermined positional relationship).
    Type: Application
    Filed: June 10, 2019
    Publication date: August 26, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shunsuke YAMAMOTO, Shinichi MATSUMOTO, Hideki HIRABAYASHI
  • Patent number: 11098132
    Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: August 24, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Dirk Voelkel, Robert Pachlinger, Hanspeter Rottensteiner, Alfred Weber, Andrea Engelmaier
  • Publication number: 20210254014
    Abstract: The present invention relates to a method for producing an insulin-producing cell population or a pancreatic ? cell population having the reduced number of Ki67-positive cells, comprising treating a population of endocrine progenitor cells or cells at a later stage of differentiation with an FGFR1 inhibitor.
    Type: Application
    Filed: April 22, 2019
    Publication date: August 19, 2021
    Applicants: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Noriko YAMAZOE, Hideyuki HIYOSHI, Taisuke MOCHIDA, Ryo ITO, Taro TOYODA, Azuma KIMURA
  • Patent number: 11090583
    Abstract: This disclosure relates to a bottom section for being connected to an assembly for separating a solid component from a fluid. The assembly includes an inclined plate settler with at least one sedimentation channel for letting a solid component to be separated settle, said plate settler comprising a lower portion and an upper portion, wherein said at least one sedimentation channel extends from the lower portion to the upper portion. The bottom section is configured to be connected to the lower portion of the inclined plate settler. The bottom section comprises at least one inlet channel for feeding a fluid comprising the solid component to be separated to the plate settler, and at least one collection channel for collecting a settled solid component descending from the at least one sedimentation channel.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 17, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Nikolaus Hammerschmidt, Alois Jungbauer, Hannah Engelmaier
  • Patent number: 11084884
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: August 10, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • Patent number: 11066362
    Abstract: The present invention provides a production method of a 3-cyanopyrrole compound possibly useful as an intermediate for pharmaceutical products. A production method of compound (II) including subjecting compound (I) to a reduction reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst. A production method of compound (III) including subjecting compound (I) to a reduction reaction followed by a cyclization reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: July 20, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takashi Ouchi, Giho Goh, Sunmi Kim, Jinsoon Choi, Hunsoo Park
  • Patent number: 11059780
    Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: July 13, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaki Daini, Yuhei Miyanohana, Satoshi Mikami, Yuichi Kajita, Masaki Ogino, Tatsuki Koike, Kohei Takeuchi